» Articles » PMID: 38651450

Pathophysiology, Clinical Manifestations and Diagnosis of Immune Thrombocytopenia: Contextualization from a Historical Perspective

Overview
Journal Hematol Rep
Publisher MDPI
Date 2024 Apr 23
PMID 38651450
Authors
Affiliations
Soon will be listed here.
Abstract

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by an isolated decrease in the platelet count and an increased risk of bleeding. The pathogenesis is complex, affecting multiple components of the immune system and causing both peripheral destruction of platelets and impaired central megakaryopoiesis and platelet production in the bone marrow. Here, we intend to contextualize the current knowledge on the pathophysiology, terminology, epidemiology, clinical manifestations, diagnosis, and prognosis of ITP from a historical perspective and the first references to the never-stopping garnering of knowledge about this entity. We highlight the necessity to better understand ITP in order to be able to provide ITP patients with personalized treatment options, improving disease prognosis and reducing the incidence or frequency of refractoriness.

Citing Articles

The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.

Kos M, Tomaka P, Mertowska P, Mertowski S, Wojnicka J, Blazewicz A J Clin Med. 2024; 13(22).

PMID: 39597882 PMC: 11594473. DOI: 10.3390/jcm13226738.


Treatment of Immune Thrombocytopenia: Contextualization from a Historical Perspective.

Martinez-Carballeira D, Bernardo A, Caro A, Soto I, Gutierrez L Hematol Rep. 2024; 16(3):390-412.

PMID: 39051412 PMC: 11270329. DOI: 10.3390/hematolrep16030039.

References
1.
Grozovsky R, Giannini S, Falet H, Hoffmeister K . Regulating billions of blood platelets: glycans and beyond. Blood. 2015; 126(16):1877-84. PMC: 4608239. DOI: 10.1182/blood-2015-01-569129. View

2.
Grimaldi-Bensouda L, Nordon C, Michel M, Viallard J, Adoue D, Magy-Bertrand N . Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. Haematologica. 2016; 101(9):1039-45. PMC: 5060020. DOI: 10.3324/haematol.2016.146373. View

3.
Norgaard M, Severinsen M, Maegbaek M, Jensen A, Cha S, Sorensen H . Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2012; 159(1):109-11. DOI: 10.1111/j.1365-2141.2012.09231.x. View

4.
Qu M, Liu Q, Zhao H, Peng J, Ni H, Hou M . Low platelet count as risk factor for infections in patients with primary immune thrombocytopenia: a retrospective evaluation. Ann Hematol. 2018; 97(9):1701-1706. PMC: 6097778. DOI: 10.1007/s00277-018-3367-9. View

5.
McMillan R, Tani P, Millard F, Berchtold P, Renshaw L, Woods Jr V . Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP. Blood. 1987; 70(4):1040-5. View